Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …

Advances in quantitative biomarker development have accelerated new forms of data-driven
insights for patients with cancer. However, most approaches are limited to a single mode of …

Metastatic progression is the main cause of death in cancer patients, whereas the
underlying genomic mechanisms driving metastasis remain largely unknown. Here, we …

In diffuse large B cell lymphoma (DLBCL), tumors belonging to the ABC but not GCB gene
expression subgroup rely upon chronic active B cell receptor signaling for viability, a …

Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses
may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features …

Covid-19 Antibodies after Mild Infection Among 34 volunteers who had recovered from mild
Covid-19 illness, antiviral antibodies to the receptor-binding domain of the viral spike protein …

Lung cancer is the leading cause of cancer-related death worldwide. However, lung cancer
incidence and mortality rates differ substantially across the world, reflecting varying patterns …

PURPOSE BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib
versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with …

Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …

Mutant-selective KRASG12C inhibitors, such as MRTX849 (adagrasib) and AMG 510
(sotorasib), have demonstrated efficacy in KRAS G12C-mutant cancers, including non–small …